EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NLS Pharmaceutics's Enterprise Value is $6.11 Mil.
NLS Pharmaceutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.69 Mil. Therefore, NLS Pharmaceutics's EV-to-FCF for today is -0.63.
The historical rank and industry rank for NLS Pharmaceutics's EV-to-FCF or its related term are showing as below:
NLSP'
s EV-to-FCF Range Over the Past 10 Years
Min: -45.61 Med: 0 Max: 0
Current: -0.45
NLSP's EV-to-FCF is ranked worse than 100% of 378
companies
in the Biotechnology industry
Industry Median: 8.59
vs NLSP: -0.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for NLS Pharmaceutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NLS Pharmaceutics's EV-to-FCF
For the Biotechnology subindustry, NLS Pharmaceutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NLS Pharmaceutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NLS Pharmaceutics's EV-to-FCF falls into.
NLS Pharmaceutics's current Enterprise Value is $6.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NLS Pharmaceutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NLS Pharmaceutics's PE Ratio for today is calculated as:
NLS Pharmaceutics's share price for today is $0.177.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NLS Pharmaceutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NLS Pharmaceutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of NLS Pharmaceutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
NLS Pharmaceutics (NLS Pharmaceutics) Business Description
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NLSP has been successfully added to your 